(4-methyl-2-p-tolyl-thiazol-5-yl)-methanol | 61291-92-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (4-methyl-2-p-tolyl-thiazol-5-yl)-methanol
• 英文别名: 5-hydroxymethyl-2-(4-methylphenyl)-4-methyl-1,3-thiazole；5-Thiazolemethanol, 4-methyl-2-(4-methylphenyl)-；[4-methyl-2-(4-methylphenyl)-1,3-thiazol-5-yl]methanol
• CAS: 61291-92-7
• 化学式: C₁₂H₁₃NOS
• 分子量: 219.307
• InChiKey: QYAGSFJEQWCWFD-UHFFFAOYSA-N

物化性质

• 熔点：
  107-109 °C
• 沸点：
  393.8±44.0 °C(Predicted)
• 密度：
  1.193±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  61.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (4-methyl-2-p-tolyl-thiazol-5-yl)-methanol 在 2-碘酰基苯甲酸 作用下， 以 二甲基亚砜 为溶剂， 生成 4-methyl-2-p-tolyl-thiazole-5-carbaldehyde
  参考文献：
  名称：

  微波辅助无溶剂合成一些新型噻唑取代缩氨基硫脲类似物：抗菌和抗癌研究

  摘要：

  对抗生素耐药性的增加迫使研究人员设计针对多重耐药病原微生物的新型活性化合物。通过氨基硫脲与2-芳基-4-甲酰基噻唑、2-芳基-5-甲酰基-4-甲基噻唑和/或5-乙酰基-2-芳基-4-甲基噻唑化合物反应合成了一系列缩氨基硫脲衍生物。评估了这些基于缩氨基硫脲的噻唑加合物对结核病 H37Ra 和牛 BCG 分枝杆菌的抑制活性。他们针对两种癌细胞系评估了它们的细胞毒性：结肠癌（HCT-116）和宫颈癌（HeLa）。值得注意的是，即使在最高浓度下，这些缩氨基硫脲对这些细胞系也表现出最小的细胞毒性作用。此外，所制备的缩氨基硫脲衍生物对枯草芽孢杆菌和金黄色葡萄球菌（革兰氏阳性细菌病原体）以及大肠杆菌和荧光假单胞菌（革兰氏阴性细菌病原体）具有显着的抗菌功效。虽然大多数制备的缩氨基硫脲衍生物对白色念珠菌（一种真菌菌株）表现出中等活性，但其性能值得注意。缩氨基硫脲基噻唑加合物也采用无溶剂方法在微波辐射下成功合

  DOI：

  10.1002/bio.4587
• 作为产物：
  描述：

  4-methyl-2-p-tolyl-thiazole-5-carbaldehyde 在 sodium tetrahydroborate 、 乙醇 作用下， 反应 2.0h， 生成 (4-methyl-2-p-tolyl-thiazol-5-yl)-methanol
  参考文献：
  名称：

  作为癌细胞线粒体靶向抑制剂的新型噻唑衍生物的设计、合成和生物学评价

  摘要：

  线粒体是细胞维持必要代谢活动的关键能量生产来源。针对功能失调的线粒体特征一直是线粒体相关疾病研究的热点。对癌性线粒体代谢的研究是肿瘤治疗中持续关注的问题。在此，我们基于我们早期对线粒体靶向剂的研究，着手评估新型 TPP-噻唑衍生物家族的抗癌活性。具体而言，我们设计并合成了一系列 TPP-噻唑衍生物，并通过 MTT 测定显示大多数合成的化合物有效抑制了三种癌细胞系（HeLa、PC3 和 MCF-7）。在结构修改后，我们探索了 SAR 关系并确定了最有希望的化合物R13（IC50 of 5.52 μM) 用于进一步研究。同时，我们进行了 ATP 产生测定以评估所选化合物对 HeLa 细胞能量产生的抑制作用。结果显示测试化合物显着抑制癌细胞的ATP产生。总体而言，我们设计并合成了一系列对癌细胞具有显着细胞毒性并有效抑制线粒体能量产生的化合物。

  DOI：

  10.1016/j.bioorg.2021.105015

文献信息

• Design, synthesis and Structure–activity relationship studies of new thiazole-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes
  作者：Zheng Li、Qianqian Qiu、Xue Xu、Xuekun Wang、Lei Jiao、Xin Su、Miaobo Pan、Wenlong Huang、Hai Qian

  DOI：10.1016/j.ejmech.2016.02.040

  日期：2016.5

  The free fatty acid receptor 1 (FFA1/GPR40) has attracted interest as a novel target for the treatment of type 2 diabetes. Several series of FFA1 agonists including TAK-875, the most advanced compound terminated in phase III studies due to concerns about liver toxicity, have been hampered by relatively high molecular weight and lipophilicity. Aiming to develop potent FFA1 agonists with low risk of

  游离脂肪酸受体1（FFA1 / GPR40）作为治疗2型糖尿病的新靶标已引起人们的关注。相对较高的分子量和亲脂性阻碍了包括FAK1激动剂在内的数个系列的FFA1激动剂（由于对肝毒性的担忧而在III期研究中终止的最先进的化合物）。为了通过降低亲脂性来开发具有低肝毒性风险的有效FFA1激动剂，TAK-875的中间苯基被11个极性五元杂芳族化合物所取代。随后，对SAR的系统探索和分子建模的应用导致了化合物44的鉴定，它是一种出色的FFA1激动剂，在正常和2型糖尿病小鼠中均具有强大的降血糖作用，即使在两倍摩尔的TAK-875剂量下也具有低血糖风险和肝毒性。同时，指出了两个重要发现。首先，我们的噻唑系列中的甲基占据了一个小的疏水亚口袋，与TAK-875没有相互作用。此外，激动活性显示与噻唑核心和末端苯环之间的二面角具有良好的相关性。这些结果促进了对配体结合口袋的了解，并可能有助于设计更有希望的FFA1激动剂。
• Synthesis, antitubercular and antimicrobial potential of some new thiazole substituted thiosemicarbazide derivatives
  作者：Yogita K. Abhale、Abhijit Shinde、Keshav K. Deshmukh、Laxman Nawale、Dhiman Sarkar、Pravin C. Mhaske

  DOI：10.1007/s00044-017-1955-1

  日期：2017.10

  resistance due to multiple factors has warranted the need for search of new compounds which are active against multidrug resistant pathogens. In this context a small focused library of thiosemicarbazide derivatives of 2-arylthiazole-4-carbaldehyde, 4-methyl-2-arylthiazole-5-carbaldehyde and 1-(4-methyl-2-arylthiazol-5-yl) ethanone, (5a–l) has been synthesized. The title compounds were screened for inhibitory

  由于多种因素引起的抗生素耐药性的增加，保证了需要寻找对多药耐药病原体具有活性的新化合物。在这种情况下，一个小型的图书馆集中了2-芳基噻唑-4-甲醛，4-甲基-2-芳基噻唑-5-甲醛和1-（4-甲基-2-芳基噻唑-5-基）乙酮的硫代氨基脲衍生物（5a – l）已合成。筛选标题化合物对结核分枝杆菌H37Ra（ATCC 25177）和牛分枝杆菌Bacille Calmette Guerin菌株（ATCC 35743）的抑制活性。合成的化合物5a – l进一步测定了它们对两种人癌细胞系HeLa和人结肠癌116细胞系的细胞毒活性，并且在所评估的最大浓度下对这两种细胞系没有明显的细胞毒活性。此外，发现合成的化合物对革兰氏阴性菌，大肠杆菌，假单胞菌荧光和革兰氏阳性菌，金黄色葡萄球菌，枯草芽孢杆菌具有潜在的抗菌活性。大多数合成化合物对真菌菌株白色念珠菌具有中等活性。这项研究为我们正在进行的合理设计更有效的抗分枝杆菌药物的努力提供了宝贵的指导。
• PROCESS FOR PREPARING LIGANDS OF PPARDELTA AND THE INTERMEDIATE COMPOUNDS FOR PREPARING THE SAME
  申请人：Kang Heon Joong

  公开号：US20110184186A1

  公开（公告）日：2011-07-28

  The present invention provides a process for preparing thiazole derivatives of formula (I), that activate the delta subtype of the human Peroxisome Proliferator Activated Receptor (hPPAR δ), and also provides compounds of formula (II), (IV), (X), (XI) and (XII), intermediate compounds for preparation of the above compounds of formula (I).

  本发明提供了一种制备式(I)的噻唑衍生物的过程，该衍生物能激活人类过氧化物酶体增殖物激活受体(hPPARδ)的δ亚型，并提供了式(II)、(IV)、(X)、(XI)和(XII)的化合物，这些化合物是上述式(I)的制备的中间体。
• Synthesis, antimycobacterial screening and molecular docking studies of 4-aryl-4′-methyl-2′-aryl-2,5′-bisthiazole derivatives
  作者：Yogita K. Abhale、Abhijit D. Shinde、Keshav K. Deshmukh、Laxman Nawale、Dhiman Sarkar、Prafulla B. Choudhari、Santosh S. Kumbhar、Pravin C. Mhaske

  DOI：10.1007/s00044-017-1988-5

  日期：2017.11

  A series of 4-aryl-4'-methyl-2'-aryl-2,5'-bisthiazole derivatives (5a-o) were synthesized and screened for inhibitory activity against Mycobacterium tuberculosis H37Ra (ATCC 25177) and Mycobacterium bovis BCG (ATCC 35743) strains. Five lead compounds (5e, 5f, 5g, 5h, and 5o) were further confirmed from their dose dependent effect against MTB and Bovine-Calmette-Guerin. The most promising compounds 5f (MIC90: 11.32 mu g/mL), 5h (MIC90: 11.59 mu g/mL), and 5o (MIC90: 23.64 mu g/mL) showed strong antitubercular activity against dormant MTB and BCG as well as almost insignificant cytotoxicity up to 100 mu g/mL against HeLa, A549, and PANC-1 human cancer cell lines. Further, the synthesized compounds were found to have potential antibacterial activity against Gram-negative bacteria, Escherichia coli, Pseudomonas flurescence and Gram-positive bacteria, Staphylococcus aureus, Bacillus subtilis. Most of the synthesized compounds showed moderate activity against fungal strain Candida albicans. Molecular docking studies of these compounds showed significant interactions with crystal structure of the cytochrome P45014 alpha-sterol demethylase (CYP51) PDB ID: 1E9X. Hydrogen bond interactions with SER261 and VAL395 are important interactions for selective inhibition of designed inhibitors. Compounds 5f, 5h, and 5o showed significant interactions with 1E9X. All the experimental results promote us to consider this series as a starting point for the development of novel, selective and more potent antitubercular agents in the future.
• Synthesis and antimycobacterial evaluation of new 5-(1-benzyl-1H-1,2,3-triazol-4-yl)-4-methyl-2-arylthiazole derivatives
  作者：Vikas Shinde、Pramod Mahulikar、Pravin C. Mhaske、Shakti Chakraborty、Amit Choudhari、Siddharth Phalle、Prafulla Choudhari、Dhiman Sarkar

  DOI：10.1007/s00044-019-02310-y

  日期：2019.6

  A new series of 5-(1-benzyl-1H-1,2,3-triazol-4-yl)-4-methyl-2-arylthiazole derivatives, 6a-w have been synthesized by click reaction of substituted benzylazide, 5a-d with 5-ethynyl-4-methyl-2-substituted phenylthiazole, 4a-f. The starting compounds 4-ethynyl-2-substituted phenylthiazole (4a-f) were synthesized from the corresponding thiazole aldehyde by using the Ohira-Bestmann reagent. The structure of the synthesized compounds was determined by spectral analysis. All the synthesized compounds were screened for their preliminary antitubercular activity against Mycobacterium tuberculosis H37Ra (MTB, ATCC 25177). Most of the synthesized compounds reported good activity against M. tuberculosis H37Ra strain with IC50 range of 0.58-8.23 mu g/mL. Compounds 6g and 6k reported good antitubercular activity with MIC90 values of 4.71 and 2.22 mu g/mL, respectively. Potential antimycobacterial activity suggested that these compounds could serve as good lead compounds for further optimization and development of a newer antitubercular candidate.[GRAPHICS].